Kringle Pharma, Inc.
Kringle Pharma, Inc. (4884.T) Financial Performance & Income Statement Overview
Review Kringle Pharma, Inc. (4884.T) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Kringle Pharma, Inc. (4884.T) Income Statement & Financial Overview
Analyze Kringle Pharma, Inc.’s 4884.T earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $18.16M | $18.51M | $18.46M | $24.34M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $18.16M | $18.51M | $18.46M | $24.34M |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $0.00 | $643.00M | $0.00 | $165.66M |
| SG&A Expenses | $230.35M | $387.22M | $231.44M | $222.00M |
| Operating Expenses | $230.35M | $255.78M | $231.44M | $222.49M |
| Total Costs & Expenses | $230.35M | $255.78M | $231.44M | $222.49M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $212.19M | $237.28M | $212.97M | $197.00M |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$212.19M | -$237.28M | -$212.98M | -$198.15M |
| Operating Income Ratio | -$11.68 | -$12.82 | -$11.53 | -$8.14 |
| Other Income/Expenses (Net) | -$118000.00 | -$419000.00 | $61.14M | $1.80M |
| Income Before Tax | -$212.31M | -$237.70M | -$151.83M | -$196.36M |
| Income Before Tax Ratio | -$11.69 | -$12.84 | -$8.22 | -$8.07 |
| Income Tax Expense | $372000.00 | $118000.00 | $372000.00 | $374000.00 |
| Net Income | -$212.68M | -$237.58M | -$152.20M | -$196.73M |
| Net Income Ratio | -$11.71 | -$12.84 | -$8.24 | -$8.08 |
| EPS | -$31.23 | -$34.92 | -$22.96 | -$30.62 |
| Diluted EPS | -$31.23 | -$34.92 | -$22.96 | -$30.62 |
| Weighted Avg Shares Outstanding | $6.81M | $6.80M | $6.63M | $6.43M |
| Weighted Avg Shares Outstanding (Diluted) | $6.81M | $6.80M | $6.63M | $6.43M |
Over the last four quarters, Kringle Pharma, Inc.'s revenue moved from $24.34M in Q2 2024 to $18.16M in Q1 2025. Operating income in Q1 2025 was -$212.19M, with a strong operating margin of -1168%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Kringle Pharma, Inc. remained robust at $0.00, reflecting operational efficiency. Net income rose to -$212.68M, with an EPS of -$31.23. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan